Navigation Links
The Scientific Business of Thomson Reuters Publishes Its 2008 Liquent Regulatory Affairs Trends Survey Results
Date:7/16/2008

Survey Highlights Trends In eCTD Migration And Submissions Outsourcing And Provides Insights Into Regulatory Product Management Trends Across North

America And Europe

PHILADELPHIA and LONDON, July 17 /PRNewswire/ -- The Scientific business of Thomson Reuters today announced the early findings of its 2008 Liquent Regulatory Affairs Trends Survey. The survey attracted respondents from across the globe representing small, medium and large pharmaceutical companies and provides a unique insight into emerging and future trends in regulatory product management usage and adoption.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080424/NYTH069LOGO )

Now in its sixth year and frequently sourced by pharmaceutical journals and publications across the world, this survey has become the premier benchmark of global regulatory submission trends offering timely insights into how pharmaceutical regulatory professionals use technology today and how they plan to harness technology in the future.

There were 137 Regulatory Affairs professionals working in Life Sciences companies across the globe who participated in this survey. The survey concentrates on four key areas: Technology Usage Trends, including both submission publishing software and other desktop software, Document Management System usage, Regulatory Outsourcing trends, and Regulatory trends including use or future use of the electronic Common Technical Document (eCTD).

The demographic make-up of the respondent population is similar to previous years with almost one third working in large pharmaceutical companies (32%) and more than a third working in small to medium companies (36%). Another 10% of respondents work for biotechnology companies. There were significantly more respondents from Contract Research Organizations (CROs) in 2008 (10%) than in 2007 (4%). 68% of those surveyed are from the United States and the majority of the remaining respondents are from Europe, with France (4%), Switzerland (4%), the UK (3%) and Germany (3%) the most highly represented.

Survey highlights include:

Technology Usage:

-- Almost all (92%) of the survey respondents make regulatory submissions, a slight increase on 2007 (90%); current use of paper and electronic submissions has remained the same since 2007.

-- Three-quarters (75%) are using submission publishing software, similar to 2007 (67%). Approximately one-third (31%) of those respondents not currently using software are very likely to implement submission publishing software into their process.

-- As in 2007, the SAFE initiative has not yet taken hold in most companies surveyed: only 2% of respondents are currently addressing it. However, there has been a significant increase in the percentage of companies that are currently using technology to support the FDA Gateway, up to 19% this year, from 9% in 2007.

Regulatory Outsourcing Trends:

-- 30% of respondents do not outsource any of their regulatory operations. -- Printing (28%) was the regulatory operation outsourced the most by respondents.

Regulatory Trends:

-- Eight in ten (83%) of respondents intend to migrate to the eCTD, with 20% of these reporting they will migrate within the next year.

"This year's survey has once again attracted respondents from across the breadth of the global life sciences industry, with large as well as small to medium sized companies participating," said Jim Nichols, Liquent's Vice President of Product Strategy and Marketing, who launched this worldwide initiative in 2003. "We're particularly excited to see a significant increase in the numbers of Contract Research Organizations (CROs) replying to our survey, further diversifying the population sample."

Full results of the survey are available on request at the following address: http://www.liquent.com/2008survey/

For more information about Liquent regulatory information management services, please go to: http://www.thomsonreuters.com/products_services/scientific1/liquentinsight

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to http://www.thomsonreuters.com.


'/>"/>
SOURCE Thomson Reuters
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Principle of Recursive Genome Function Supersedes Dogmas; By Andras Pellionisz, Online Ahead of Print; (Scientific Visionary Vindicated)
2. Raptor Pharmaceuticals Expands Board of Directors and Scientific Advisory Board
3. Cytopia Strengthens Scientific Team With US-Based Drug Development Specialist
4. ISMPP Applauds AAMC Clarification on Ghostwriting Versus Transparent Writing Collaboration in Scientific Publications
5. Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System
6. Exiqon Appoints Cynthia French as Chief Scientific Officer and Erik Holmlin as Chief Commercial Officer
7. Boston Scientific To Webcast Conference Call Discussing Second Quarter Financial Results
8. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
9. Iomai, Intercell Chief Scientific Officers to Speak on Future of Vaccines at BIO International Convention Today
10. Californias International Stem Cell Collaborations Must Be Based on Scientific Merit, Consumer Group Says
11. Corgenix Expands Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... BioMedGPS announces ... addition of its newest module, US Hemostats & Sealants. , SmartTRAK’s US Market ... hemostats, fibrin sealants, synthetic sealants and biologic sealants used in surgical applications. BioMedGPS ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... in its endogenous context, enabling overexpression experiments and avoiding the use of exogenous ... RNA guides is transformative for performing systematic gain-of-function studies. , This complement ...
(Date:10/11/2017)... , Oct. 11, 2017  VMS BioMarketing, a leading ... a nationwide oncology Clinical Nurse Educator (CNE) network, which will ... need for communication among health care professionals to enhance the ... nurses, office staff, and other health care professionals to help ... breast cancer. ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today announced ... to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B ... to cross the cell membrane and bind intracellular STAT3 and inhibit its function. ...
Breaking Biology Technology:
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ... appointment of independent Directors Mr. Robin D. Richards ... Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive ... their guidance and benefiting from their considerable expertise as we ...
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
Breaking Biology News(10 mins):